How many clinical trials are running for deucravacitinib?

ClinicalTrials.gov lists more than 16 phase 2–4 deucravacitinib trials. This page tracks the 16 largest by enrolment: 4 phase 2, 9 phase 3, and 3 phase 4 among them, with 2 actively recruiting. Updated daily.

Where does this data come from?

All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.

Can I compare deucravacitinib against other drugs?

Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

Immunology & inflammation · Live ClinicalTrials.gov data

Deucravacitinib (Sotyktu) clinical trial pipeline

The timeline below tracks the 16 largest phase 2–4 deucravacitinib trials on ClinicalTrials.gov by enrolment, 2 of them actively recruiting. The next phase 3 primary completion among them is expected Jul 2026. Refreshed daily — add up to four competitors to compare pipelines side by side.

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Jul 2026

Next phase 3 primary completion

10,437

Participants across trials

Bristol-Myers Squibb

Lead sponsor by trial count

deucravacitinib (16)8 active2016–2032

Hide completed

deucravacitinib

Key

Actual date

Anticipated

Forecast to primary completion

RecruitingActive, not recruitingCompletedTerminated

'16

'18

'20

'22

'24

'26

'28

'30

'32

deucravacitinib

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisP2

POETYK-PSO-2P3

POETYK-PSO-1P3

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusP2

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative ColitisP2

POETYK PSO-LTEP3

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisP3

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp PsoriasisP4

POETYK SLE-1P3

POETYK SjS-1P3

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital PsoriasisP4

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)P3

ViTYKP2

IMMpactfulP4

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque PsoriasisP3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)P3

Upcoming readouts

6 ahead · deucravacitinib

Select a trial to load its full ClinicalTrials.gov record.

Key deucravacitinib trials

Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.

Trial	Title	Phase	Status	Primary completion
NCT05478499	Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis	Phase 4	Completed	Jan 2024
NCT06333860	IMMpactful — A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants…	Phase 4	Completed	Mar 2026
NCT06042920	A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar…	Phase 4	Terminated	Apr 2025
NCT04772079	A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Partici…	Phase 3	Recruiting	Jan 2029
NCT07116967	Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)	Phase 3	Recruiting	Jan 2031
NCT06220604	A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADV…	Phase 3	Active, not recruiting	Nov 2024
NCT04036435	POETYK PSO-LTE — Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Pso…	Phase 3	Active, not recruiting	Jul 2026
NCT05617677	POETYK SLE-1 — A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Activ…	Phase 3	Active, not recruiting	Oct 2026
NCT05946941	POETYK SjS-1 — A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome	Phase 3	Active, not recruiting	Nov 2026
NCT03624127	POETYK-PSO-1 — Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasi…	Phase 3	Completed	Sept 2020
NCT03611751	POETYK-PSO-2 — An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Av…	Phase 3	Completed	Nov 2020
NCT06973291	A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis	Phase 3	Completed	Apr 2026

Compare deucravacitinib vs dupilumab Compare deucravacitinib vs lebrikizumab

FAQ

How many clinical trials are running for deucravacitinib?: ClinicalTrials.gov lists more than 16 phase 2–4 deucravacitinib trials. This page tracks the 16 largest by enrolment: 4 phase 2, 9 phase 3, and 3 phase 4 among them, with 2 actively recruiting. Updated daily.
Where does this data come from?: All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
Can I compare deucravacitinib against other drugs?: Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.

Upcoming readouts

Key deucravacitinib trials

Related drug pipelines

FAQ

Be the first to access ComplyRx